Pivotal readout

Roche's satralizumab keeps most thyroid eye disease responders through week 48

Pooled 48-week data from two Phase 3 studies, SatraGO-1 and SatraGO-2, show that about 85% of week-24 responders on satralizumab (Enspryng) were still responding at week 48. Safety data raised no new concerns and showed no serious infections. The IL-6 receptor antibody won US approval for adults with thyroid eye disease last month and has been filed in China.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Schematic animation of IL-6 binding its receptor and the gp130 partner on a cell, the antibody satralizumab attaching to soluble and cell-surface IL-6 receptors so IL-6 cannot signal, and the antibody releasing inside an acidic compartment and returning to the blood.
Satralizumab: blocking the IL-6 receptor. Watch the mechanism animation on the satralizumab page.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call